期刊文献+

两种测定血清半胱氨酸蛋白酶抑制剂C方法的结果比较 被引量:3

暂未订购
导出
摘要 目的了解颗粒增强散射免疫比浊法(PENIA)和颗粒增强透射免疫比浊法(PETIA)测定血清半胱氨酸蛋白酶抑制剂C(Cys C)结果的相关性,为不同的方法学检测血清Cys C是否具有一致性提供参考依据。方法按照美国临床实验标准化委员会(NCCLS)EP9-A文件进行评估,将测得的数据进行相关回归分析,计算2种方法间的偏倚。结果PENIA和PETIA测定Cys C的相关方程为YPETIA=1.352XPEN IA-0.009,相关系数(r)=0.976。结论这2种方法测定血清Cys C有良好的相关性。当实验室内同一项目存在2套以上分析系统检测时,应对其进行对比分析和偏倚评估,为室间评价结果提供参考依据。
出处 《检验医学》 CAS 北大核心 2008年第5期520-522,共3页 Laboratory Medicine
  • 相关文献

参考文献6

二级参考文献58

  • 1李海霞,张春丽,徐国宾,王学晶,李淑葵,李志艳,张旭初,夏铁安.健康人群血清半胱氨酸蛋白酶抑制剂C与肌酐分布及其评价慢性肾脏病患者肾小球滤过功能的比较研究[J].中华检验医学杂志,2006,29(11):970-974. 被引量:179
  • 2艾洪武,陈莎,邱艳,孙红,游上游.血清γ-痕迹蛋白在儿童肾脏疾病中的应用价值[J].临床儿科杂志,2006,24(12):987-989. 被引量:2
  • 3Abrahamson M,Mason RW,Hansson H,et al. Human cystatin C.role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leucocyte elastase. Biochem J, 1991,273:621-626.
  • 4Grubb A.Diagnostic value of analysis of cystatin and protein HC in biological fluids.Clin Nephol,1992,38 suppl 1:S 20-27
  • 5Ekiel I,Abrahamson M,Fulton DB,et al. NMR Structural studies of human cystatin C dimmers and monomers. J Mol Biol, 1997,271:266-277.
  • 6Thielemans N, Lauwerys R, Bernard A. Competition between albumin and low-molecular-weight protein for renal tubular uptake in experimental nephropathies. Nephron, 1994, 66:453-458.
  • 7Joronen I,Hopsu-Havu VK,Rinne A,et al. Detection of low molecular weight cysteine proteinase inhibitors by time-resolved fluoroimmunoassay. J Immunal Meth, 1986,86:243-247.
  • 8Colle A,Tavera C,Prevot D,et al. Cystatin C levels in sera of patein with human immunodeficiency virus infection. J immunoassay,1992,13:47-60.
  • 9Newman DJ.Cystatin C. Ann Clin biochem,2002,39:89-104.
  • 10Fanos V,Mussap M,Plebani M,et al. Cystatin C in paediatric nephrology, present situation and propect. Minerva Pediatr,1999,51:167-177.

共引文献194

同被引文献34

  • 1李海霞,吴红花,徐国宾,郭晓蕙,夏铁安.血清半胱氨酸蛋白酶抑制剂C与肌酐在评价糖尿病患者肾小球滤过功能中的比较研究[J].中华检验医学杂志,2005,28(6):602-605. 被引量:107
  • 2李海霞,张春丽,徐国宾,王学晶,李淑葵,李志艳,张旭初,夏铁安.健康人群血清半胱氨酸蛋白酶抑制剂C与肌酐分布及其评价慢性肾脏病患者肾小球滤过功能的比较研究[J].中华检验医学杂志,2006,29(11):970-974. 被引量:179
  • 3National Committee for Clinical Standards. Method comparison and bias estimation using patient samples; approved guideline-second edition [ S ]. EP9-A2, NCCI_S,2002.
  • 4Hossain MA, Emara M, E1 Moselhi H, et al. Comparing measures of cystatin C in human sera by three methods [ J]. Am J Nephrol, 2009 , 29 (5) : 381-391.
  • 5National Committee for Clinical Standards. Method comparison and bias estimation using patient samples; approved guideline [ S ]. EP9-A, NCCLS, 1995.
  • 6International Organization for Standardization. In vitro diagnostic medical devices. Measurement of quanti- ties in biological samples. Metrological traceability of values assigned to calibrators and control materials [S]. IS017511,IS0, 2003.
  • 7Grubb A, Blirup-Jensen S, Lindstrom V. First certified reference material for cystatin C in human serum ERM-DA471/IFCC [ J ]. Clin Chem Lab Med, 2010, 48 (11) : 1619-1621.
  • 8Voskoboev NV, Larson TS, Rule AD, et al. Importance of cystatin C assay standardization [ J ]. Clin Chem, 2011, 57 (8): 1209-1211.
  • 9Dharnidharka VR,Kwon C,Stevens G. Serum cystatinC is superior to serum creatinine as a marker of kid-ney function : a meta-analysis[ J] . Am J Kidney Dis,2002,40(2) :221-226.
  • 10Clinical and Laboratory Standards Institute. Evalua-tion of precision performance of quantitative measure-ment methods ; approved guideline-second edition[S].EP5-A2,CLSI,2004.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部